北京大学的研究团队在日内瓦发明展上获得了最高荣誉, 获奖者是治疗大动脉瘤和肝脏疾病方面的突破. Peking University team wins top honors at Geneva invention fair for breakthroughs in treating aortic aneurysms and liver disease.

北京大学健康科学中心的研究小组在第51届日内瓦国际发明展上获得金银奖牌, 这是他们第一次参加. A research team from Peking University Health Science Center won gold and silver medals at the 51st International Exhibition of Inventions Geneva, marking their first participation. 由张和西安顺德领导的团队提出了两项医学创新:一种针对腹腔大动脉瘤 (以前无法治愈的疾病) 的KIF13B治疗方法,以及用于治疗肝纤维化和动脉硬化的癌症药物NX-1607的重新用途. Led by Zhang Ling and Xian Xunde, the team presented two medical innovations: a KIF13B-targeted therapy for abdominal aortic aneurysm, a previously incurable condition, and repurposing of the cancer drug NX-1607 to treat liver fibrosis and atherosclerosis. 这两个项目都确定了关键的生物机制,并支持多向药物开发. 两项项目均获得国内专利, 并正在寻求国际保护. Both projects, which identified key biological mechanisms and support multi-target drug development, have received domestic patents and are seeking international protection. 欧洲心脏杂志的总编辑赞扬这项工作,旨在减少对昂贵医疗器械和长期药物治疗方案的依赖,支持中国"健康中国2030年"目标. The work, praised by the European Heart Journal’s editor-in-chief, aims to reduce reliance on expensive medical devices and long-term drug regimens, supporting China’s “Healthy China 2030” goals.